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Summary. The Barcelona Knowledge Hub of the Academia Europaea (AE-
BKH)was set up in Barcelona in 2013 as the office for the Southern European 
region and the Mediterranean. The Academia Europaea is a pan-European, 
nongovernmental, not-for-profit association of over 4000 individual scien-
tists and scholars who are recognized as experts and leaders in their own 
fields. It is committed to identifying topics of trans-European importance to 
science and scholarship, and provides, where appropriate, its expertise and 
its independent and impartial advice to European institutions, governments 
and international agencies concerning matters affecting science, scholarship 
and academic life in Europe. The AE-BKH organizes multidisciplinary activities 
that consider the perspective of the social sciences and the humanities, with 
scholarly aims as well as the goal of promoting the dissemination of science. 
One of the very special activities of the AE-BKH is the celebration of the pres-
ent-day Disputatio of Barcelona as a remembrance of the original Disputatio 
of Barcelona held in 1263.Until present, four moder-day Disputationes have 
been held, from 2013 until 2016 [Contrib Sci 12(2):83-91 (2016)]
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The Academia Europaea, 
promoting learning, education 
and research
The Academia Europaea (AE), founded in 1988, is a pan-Euro-
pean, nongovernmental, not-for-profit association of indi-
vidual scientists and scholars who are elected by nomination 
and recognized by their peers as experts and leaders in their 
fields. The AE is independent of national governments and 
government-controlled sources of finance. Its main object is 
to support the culture of European research through dia-
logue and collaboration. 
In its mission statement, the AE is committed to identify-
ing topics of trans-European importance to science and 
scholarship, and to proposing appropriate action to ensure 
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that these topics are adequately addressed. It promotes a 
wider appreciation of the value of European scholarship and 
of research and encourages interdisciplinary and internation-
al scholarship in all areas of learning of relevance to Europe. 
In addition, where appropriate to its expertise, it provides 
independent and impartial advice to European institutions, 
governments and international agencies concerning matters 
affecting science, scholarship and academic life in Europe. 
The AE-Barcelona Knowledge 
Hub: the Southern European and 
Mediterranean Office 
In 2013, the AE-BKH was established in Barcelona as the office 
for the Southern European region and the Mediterranean. 
Barcelona has a strong academic and scientific environment, 
with important centres for biomedicine and photonics. In addi-
tion, the city is one of the main Euro-Mediterranean centres 
and the capital of the Union for the Mediterranean. Thus, the 
AE-BKH contributes towards the consolidation of the city’s in-
ternational position. This explains the decision by the Catalan 
Government (Ministry of Economy and Knowledge), the Barce-
lona City Council and the “la Caixa” Foundation to join efforts 
to launch an AE hub in Barcelona. The AE-BKH is housed on the 
premises of the Institute for Catalan Studies (IEC) (Fig.1). 
One of its main objectives is to organize multidisciplinary 
activities that include the perspective of the social sciences 
and the humanities in the southern European region, with 
scholarly aims and for the dissemination of science.
The Disputationes of Barcelona
 The BKH’s inaugural event was celebrated in November 2013 
as a commemoration of the 750th anniversary of the Dispu-
tatio of Barcelona, by holding its own, present-day Disputatio 
of Barcelona (Fig. 2). The first Disputatio of Barcelona was 
held in 1263 before King James I of Aragon; it was one of the 
inter-faith debates that took place between Christian and 
Jewish theologians. On that occasion, the debaters were Pau 
Cristià, a convert from Judaism and a Dominican friar, and 
Rabbi Moses ben Nahman (also known as Nahmanides; his 
Catalan name was Bonastruc ça Porta), a Catalan Sephardic 
rabbi, physician, philosopher, kabbalist and biblical commen-
tator. In the scholastic system of education of the Middle 
Ages, the Disputationes offered a formalized method of de-
bate designed to uncover and establish truths in theology 
and the sciences. Fixed rules governed the process: they de-
manded dependence on traditional written authorities and a 
thorough understanding of the argument made by each side.
The 2013 Disputatio of Barcelona, with the title “Social 
and State-of-the-Art Medicine,” took place on November 
28th in the historical Main Hall (Saló de Cent) of the Barce-
lona City Hall, before over two hundred members of the local 
scientific, intellectual community. The event was hosted by 
Fig. 1. The AE-BKH is housed on the the Institute for Catalan Studies (IEC).
Fig. 2. Panoramic view of the Disputatio of Barcelona 2013, held in the Saló de Cent of the Barcelona City Hall. 
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Xavier Trias (at that time Mayor of Barcelona), who was 
joined at the presidential table by Lars Walloe and Anne Butt-
imer (former President and Vice-President of the AE, respec-
tively), Andreu Mas-Colell (at that time Minister of Economy 
and Knowledge of the Catalan Government) and the by 
Genoveva Martí (at that time the academic director of the 
AE-BKH). Two speakers with expertise in different areas were 
invited to share their views on the access to medical resourc-
es and their distribution (Fig. 3). 
In keeping with the AE-BKH’s intent to approach issues 
from a multidisciplinary perspective, the invited disputantes 
were Mara Dierssen, a neuroscientist, group leader of Cellu-
lar and Systems Neurobiology of the Systems Biology Pro-
gramme at the Centre for Genomic Regulation in Barcelona, 
and president of the Spanish Society for Neuroscience, and 
Thomas Pogge, a philosopher, president of the Health Impact 
Fund, Leitner Professor of Philosophy and International Af-
fairs at Yale University, director of the Global Justice Program 
and Board Member of Academics Stand Against Poverty.
The success of the event inspired the advisory board of 
the BKH to continue holding Disputationes as the main an-
nual event of the BKH. 
The 2014 Disputatio of Barcelona was organized in con-
junction with the United Nations University. It was held in 
November 2014, on the premises of the Hospital de Sant Pau 
of Barcelona, declared a World Heritage Site by UNESCO in 
1997, under the title “The Mediterranean, bridge of cul-
tures”. The 2014 disputantes were Maria Paradiso, Full Pro-
fessor of Geography and Planning at the University of Sannio, 
Italy, and Enric Banda, at that time Director of Science and 
Environment at the “la Caixa” Foundation 
The 2015 Disputatio of Barcelona was held on December 
2015 at the Gothic Royal Chapel of St. Agatha, viewing the 
famous Epiphany altarpiece by Jaume Huguet (1412−1492) 
with the title of “Natural vs. Artificial Intelligence”. The dispu-
tantes, again a woman and a man, were Núria Sebastián, vi-
cepresident of the Scientific Council of the European Re-
search Council and leader of the SAP Research Group (Speech 
Acquisition and Perception) at the Universitat Pompeu Fabra, 
and Ulises Cortés, Full Professor and researcher of the Tech-
nical University of Catalonia (UPC). 
The 2016 Disputatio of Barcelona has been the last one. 
It was held on November 2016 at the premises of the Gen-
eralitat de Catalunya (a Gothic building from the 14th cen-
tury) after a protocolary reception with Mr. Carles Puigde-
mont, President of the Catalan Government. The topic for 
Fig. 3. From left to right: Genoveva Martí (Academic Director of the Barcelona Knoledge Hub), Lars Walløe (President of 
the Academia Europaea), Xavier Trias (Mayor of Barcelona), Mara Dierssen and Thomas Pogge (disputantes), Anne Butti-
mer (Vice-President of the Academia Europaea) and Andreu Mas-Colell (Minister of Economy and Knowledge of the Go-
vernment of Catalonia), at the Disputatio of Barcelona 2013.
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the Disputatio was “Natural Life vs. Synthetic Life”, and the 
disputantes, as always, a man and a woman, were Anna 
Veiga (UPF), former director of In Vitro Fertilization Labora-
tory of the Department of Obstetrics, Gynecology and Re-
production Service Reproductive Medicine at the Dexeus 
University Institute and former Chair of the Special Interest 
Group on Stem Cell, and Ricard Solé, ICREA research profes-
sor and head of the Complex Systems Lab, located at the 
PRBB (Biomedical Research Park).
The Disputatio of Barcelona 
2013: Social and State-of-the-Art 
Medicine
Human progress has two interlinked components: innovation 
(i.e., creation, invention, and discovery), and diffusion (i.e., 
the dissemination and uptake of knowledge). In the realm of 
human healthcare and drug discovery, innovative products 
can be defined as those that cure or prevent a disease or con-
dition, decrease mortality or morbidity, decrease the cost of 
care, improve the quality of life, are safer or easier to use, or 
improve patient compliance and persistence.
Presentation by Mara Dierssen:
ProDucing Progress? issues to consiDer
Pharmaceutical innovation 
In recent years, there has been a decrease in the number of 
molecular entities or biological license applications that 
have been approved. Why is this? In the USA, one impor-
tant reason is that the FDA’s approval process, driven by ex-
treme caution, is extremely long (10−15 years from the dis-
covery to the final approval). 
The January 2013 issue of The Economist contained an 
article with the title “Has the ideas machine broke down?” 
The argument was that entrepreneurs are not leading new, 
fundamental discoveries, but are simply profiting from 
knowledge coming from academia, from publicly funded re-
search: “Almost no entrepreneurs discover things funda-
mentally new, at least while working on their own nickel. 
Rather, in the words of Isaac Newton, they stood on the 
shoulders of giants. In this case, the giants were those sci-
entists and engineers funded by society, through taxpayer 
largess, that created the building blocks that led to many of 
the technological breakthroughs we have today.”
The new science of personalized medicine 
and the genomic era
Publicly funded research has powered a completely new field 
of medicine, with a completely new landscape. This knowl-
edge has radically changed the strategies for targeting diseas-
es. Some examples of this new landscape are genomic medi-
cine, the ENCODE project, synthetic biology, and robotics.
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Genoveva Martí graduated from the University of Bar-
celona and obtained her PhD from Stanford Univer-
sity. She is Research Professor of ICREA (Catalan Insti-
tute for Research and Advanced Studies) at the De-
partment of Philosophy of the University of Barcelo-
na. Before moving to Barcelona she was Reader at the 
London School of Economics. She taught also at the 
University of Washington, Seattle and the University 
of California, Riverside. In 2014–15 she was Professor 
of Philosophy at Western University in Canada. Since 
2009 she is a member of the Philosophy, Theology and 
Religious Studies Section of the AE and was elected to 
the section committee in 2015. She is a member of 
the LOGOS research group. Her research interests in-
clude the theory of reference, the semantics of singu-
lar and general terms, and the role of experimental 
data in semantics. She was awarded the Narcís Mon-
turiol Medal by the Government of Catalonia in 2012. 
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Genomic medicine
Genomic medicine has provided an abundance of informa-
tion about the genetic basis of disease, thus providing in-
sight into the physiopathology of disease and identifying 
new therapeutic targets. 
This knowledge is driving a major change in how medi-
cine is perceived; a revolution is under way, based on per-
sonalized genomics and direct-to-consumer genomic ser-
vices. Genomic medicine is driving a new approach to ther-
apy, based on a new medical model, personalized medicine. 
This model proposes customizing healthcare via decisions 
and practices tailored to the individual patient, by exploit-
ing genetic and other relevant information. Consider that, 
for a single patient group with the same diagnosis and 
treated with the same medication, there will be respond-
ers, non-responders, and those who exhibit signs of in-
creased drug toxicity. Personalized medicine, by tailoring 
medications based on genetic information, will greatly con-
tribute to optimizing treatment.
The ENCODE project
The Encyclopedia of DNA Elements (ENCODE) project is a 
public research consortium that was launched in Septem-
ber 2003 by the US National Human Genome Research In-
stitute (NHGRI) to identify all functional elements in the hu-
man genome. An achievement of ENCODE has been the 
recognition that most of the non-coding DNA is involved in 
the regulation of the expressions of coding DNA, with im-
portant effects on health. 
Synthetic biology
Another major discovery that is driving and will drive a 
change in productivity is the capability of creating new life 
from inert chemicals. In 2010, Craig Venter and his team at 
the J. Craig Venter Institute reported the creation of a bac-
terial chromosome which they used to successfully replace 
the DNA of a bacterium. Similar new entities will probably 
be capable of replicating and of evolving into new forms. 
We must think about the potential uses of future new living 
organisms. They could be used, for example, for producing 
new drugs. 
Robotics 
Brain-computer and body-computer interfaces that help 
people with disabilities to be more independent are already 
available. Computer science has contributed to improving 
not only the health, but also the social inclusion of the dis-
abled, decreasing the cost of dependency. 
Mara Dierssen 
Mara Dierssen received her degree in medicine 
(1985) from the University of Cantabria and her PhD 
(1989) from that university Department of Physio-
logy and Pharmacology. She did her postdoctoral 
work at the Autonomous University of Barcelona 
(1990–1993). She was assistant professor at the Uni-
versity of Cantabria (1993–1997), professor of psy-
chophysiology and neurosciences at Ramon Llull 
University (1997–2006), and senior researcher at the 
Medical and Molecular Genetics Centre of the Can-
cer Research Institute (IRO) in Barcelona (1997–
2001). Since 2005, she has been the director of the 
Associated Unit for Behavioral Research (National 
Biotechnology Centre-CSIC) and, since 2007, investi-
gator of the Centre for Biomedical Research on Rare 
Diseases (CIBERER). She belongs to several academic 
societies and is a member of the executive commit-
tee of the Federation of European Neuroscience So-
cieties (FENS). Dierssen has received numerous 
awards, including the National Culture Award for Sci-
ence (2008), the Sisley Lejeune Award (2010), the 
Alicia Koplowitz Award (2011), the Ramón Trías Far-
gas Award (2013), and the David and Hillie Mahoney 
Award (2014). She has published over 100 articles in 
peer-reviewed journals. Currently, she is group lea-
der of the Cellular and Systems Neurobiology of the 
Systems Biology Program at the Centre for Genomic 
Regulation (2007–) and past-president of the Spa-
nish Society for Neuroscience (2013–2015).
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Genetics, the environment, and medicine
One of the most important discoveries of recent years is that 
we can shape ourselves, both our brains and our bodies, and 
that these changes can be passed on to the next generation. 
This discovery is based on the recognition that there are 
changes in gene activity and expression that are not depen-
dent on gene sequence; moreover, they are heritable—but 
not necessarily. The study of those changes is called epi-
genetics, and the global analysis of epigenetic changes across 
the entire genome, epigenomics. Epigenomics is one of the 
fastest emerging scientific fields, promising a huge growth 
potential by revolutionizing the therapeutics and diagnostics 
industries in healthcare. The US NIH Roadmap Epigenomics 
Mapping Consortium was launched as a public resource of 
human epigenetic data to facilitate disease-oriented re-
search. 
The study of heritable changes in genome function and 
gene expression has opened a new gateway in biology, allow-
ing us to understand the basis of diseases, and presents in-
credible opportunities for disease diagnosis and drug discov-
ery. The epigenomic therapeutic market is expected to ex-
plode in the coming years. 
The problem, however, is that this basic research is lost in 
translation when it comes to converting findings into real 
therapeutic advances. The substantial increase in investment 
in pharmaceutical research has yielded only slight progress, 
since the new compounds are only marginally better, but 
much more expensive, than existing ones. Moreover, it has 
increased the gap between treatment available to the rich 
vs. the poor.
The pharmaceutical industry cannot be the ultimate an-
swer. In fact, the effects of the environment must be taken 
into account. The environment is a strong determinant of 
how we develop and function. Genetic susceptibility factors 
are responsive to environmental ones. Gene-environment 
interactions make people different, and the consequences of 
these interactions are in many cases decisive. 
Given the complexity of how phenotype is determined, 
how powerful or useful will the delineation of an individual’s 
genome be in predicting disease and in choosing therapy? 
Our understanding is far from complete; we need more basic 
science research and knowledge. Investment in science is be-
low what it should be, and we must work to improve this 
situation. 
Regarding research in medicine, there are other prob-
lems. Consider the aims of EU Horizon 2020—the eighth 
phase of the Framework Programs of Research and Techno-
logical Development, the main targets of which are aging 
and obesity. In other words, funding from public agencies is 
mostly devoted to the diseases of developed countries.
Innovation distorting economical inequalities
Focused innovation is distorted by huge economic inequali-
ties, which steer innovators away from seeking treatment of 
those diseases predominantly affecting the poor. The map 
of some disorders, such as malaria, coincides with the map 
of poverty, and is in direct opposition with the map of drug 
and pharmaceutical investment. We could appeal to ethical 
values, to morality. However, from neuroscience we know 
that power (of any kind) equals reduced morality. Policy 
proposals with ethical implications or that aim to achieve 
the egalitarian distribution of benefits and costs may fail. 
You could argue that we live in a democracy, but from 
neuroscience we also know that there are no rational vot-
ers. The political brain is an emotional brain and people are 
driven by emotions. Politicians use marketing techniques 
aimed at holding their traditional voters as well as widening 
their appeal. However, in designing their campaigns they 
should take into account voters’ attitudes, by studying how 
voters’ electoral memory, sense of responsibility, and emo-
tional state are associated with their votes. What do citizens 
think about when they stand in the polling booths? What is 
the impact of electoral arrangements on voting and voters’ 
perceptions of elections? How do voters evaluate govern-
ment performance? Answers to these questions would help 
the generation of more coherent systems. 
Concluding remarks
The health systems of most countries perform very poorly 
in terms of cost-effectiveness, which reduces their societal 
value. Overall efficiency is greatly diminished by lobbying 
and deal-making, the patent application process, litigation, 
wasteful marketing, counterfeiting, and deadweight losses. 
Adverse disturbances of drug development by the scientific 
or regulatory environment have detrimental effects on so-
cial value. Disruptions in the flow of funding from sales to 
R&D lead to lower social returns. We need to address not 
only the drivers of investment in innovation, but also how 
innovation is done. 
We need to change the model. The outcome of treat-
ment should be included in an assessment of its value. 
In other words, payment for pharmaceuticals should be 
based on performance. We should also improve science 
funding. And finally, academic knowledge, both theo-
retical and methodological, should be applied to policy 
making. 
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Presentation by thoMas Pogge:
the health iMPact FunD, a new
ParaDigM in PharMaceutical
innovation
Universal access to pharmaceutical drugs is seriously under-
mined during the time the product is under patent by large 
mark-ups. This period has been established after the Agree-
ment on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS Agreement) in 20 years. During this long period ge-
neric companies cannot work with the active molecule or ac-
tive principle, so they cannot make the so-named generic 
drugs which are much more accessible to people because its 
much lower price.
These difficulties for accessing new and cheaper drugs 
are accompanied by other characteristic of the production of 
pharmaceutical drugs by large companies—always looking 
for the higher benefit from the market—, this is the positive 
bias towards the “rich patient”, i.e. patient with a sufficient 
economic power to pay the high price of drugs. Pharmaceuti-
cal innovators can make the most money by producing drugs 
against diseases that affect the rich, affluent or well-insured 
people; they cannot make a lot of money from diseases that 
are concentrated among the world’s poorest populations. 
And for that reason, research and development of new med 
icines focuses away from large and important diseases that 
affect the poor, such as malaria, tuberculosis, schistosomia-
sis, and leishmaniasis.
An additonal problem with the current system is that 
most of the money that the world spends on pharmaceuti-
cals (about one trillion US$ every year), does not go back into 
the manufacture or the research and development of new 
drugs. Most of the money actually goes to lobbying and gam-
ing, patenting and litigating, wasteful marketing and counter-
feiting, as well as to huge deadweight losses, all of which 
greatly diminishing overall efficiency. 
The Health Impact Fund (HIF)
The solution on which we work involves the creation of the 
Health Impact Fund (HIF), which is a complement to the ex-
isting TRIPS which would offer to innovators the opportuni-
ty to voluntarily register any new medicine. For all of these 
drugs, the HIF would measure the health gains that they 
produce in the world, and would then divide the reward 
pool accordingly (about 6 billion US$ every year). Regis-
trants would be free to keep intellectual property rights, 
but would be required to sell the new medicine at the low-
est feasible average cost of manufacture and distribution 
Thomas Pogge 
Thomas Pogge received his PhD from Harvard Uni-
versity (1983). He is the Director of the Health Im-
pact Fund, Leitner Professor of Philosophy and In-
ternational Affairs and Director of the Global Justi-
ce Program at Yale. Broadly devoted to moral and 
political philosophy, and Immanuel Kant, his work 
has increasingly focused on real-world issues rela-
ted to justice, poverty and health. On these topics, 
he has led several major research collaborations 
(funded by the European Commission, the Australi-
an Research Council and the BUPA Foundation). 
Pogge’s recent publications include Politics as Usual 
(Polity 2010), World Poverty and Human Rights (Po-
lity 2008), John Rawls: His Life and Theory of Justice 
(Oxford 2007), and Freedom from Poverty as a Hu-
man Right (Oxford & UNESCO 2007). Pogge holds 
secondary appointments at King’s College London 
and at the universities of Oslo, Sydney and Central 
Lancashire. He has held visiting appointments at 
Harvard, Oslo and Princeton Universities as well as 
at the Princeton Center for Advanced Studies, All 
Souls College Oxford and the National Institutes of 
Health. Pogge is also an editor for social and politi-
cal philosophy for the Stanford Encyclopedia of Phi-
losophy. In 2013 he won the American Philosophi-
cal Association Gregory Kavka Prize in political phi-
losophy. He has received honorary doctorates from 
the universities of Turku, Bucharest and Connecti-
cut and is a member of the Norwegian Academy of 
Science.
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and to grant cost-free licenses after the reward period.
Pharmaceutical innovators will be able to choose which 
market to enter: they will be free to stay in the existing sys-
tem and get rewarded through the high mark-ups they can 
charge, protected by a patent; or they can give up that re-
ward opportunity, agree to sell their product at cost and 
then be rewarded on the basis of the health gains. Obvi-
ously, different products will choose different tracks. A prod-
uct that is mainly directed at rich people, such as a hair-loss 
product with little health gain, would stay on the patent-
track, whereas a product that addresses a need of poor peo-
ple, such as a malaria drug, would surely choose the HIF-
track, be rewarded according to health impact and sold ev-
erywhere at a low price determined by cost. 
The HIF can solve the three big problems of the status quo:
• HIF prevents high prices. All HIF-registered drugs are 
available at its real cost or even below cost from day one. 
Poor people can gain access to important new medicines 
either through their own funds or through governments, 
NGOs, or international agencies.
 • HIF also ends the neglect of the diseases of poverty. 
The HIF adds powerful targeting incentives to develop 
new drugs with the greatest health impact—regardless of 
the socioeconomic composition of patient population. 
• HIF boosts cost-effectiveness. It would reduce costs and 
losses due to patenting because innovators would not 
need to patent their drugs in many jurisdictions because 
nobody would care to compete with them if they offered 
their products at very low prices. There would be much 
less litigation and much less need for competitive market-
ing. 
As a bonus, also for rich populations, the HIF would focus 
the attention of innovators on the health of patients because 
only if you actually promote the health of patients, do you 
make money. Under the current system, by contrast, the in-
novator is rewarded for every prescription of its medicine, 
regardless of whether it is beneficial to the patient or not.
Financing the HIF. The HIF would be funded through 
governments that are willing to participate in the scheme. 
Each of them would contribute a sum around 0.03 % of their 
gross national income (GNI). The investment could be done 
through long-maturity or perpetual bonds with interest 
pegged to inflation or GNI per capita. Alternatively, the HIF 
could be funded through a dedicated international tax, for 
instance a tax on financial transactions or a tax on pollution, 
whose future revenue stream could be scrutinized. Such tax-
es would also moderate speculative excesses in financial 
markets or slow climate change. 
Ultimately, the idea is to create a diversified endowment, 
managed to generate a stable income stream that would 
cover a substantial and growing portion of the annual reward 
pools. The endowment could accept contributions also from 
international and non-governmental organizations, founda-
tions, corporations, individuals and states—following the ex-
ample of private universities. And would thereby give every-
one an opportunity personally to contribute to the long-term 
improvement of human health.
During 2013, the HIF team received €2 million from the 
European Union, which will help establish the baseline 
against which health gains will be measured. The HIF also re-
ceived a US$ 2 million commitment from Janssen Pharma-
ceutica, part of Johnson & Johnson (J&J) Pharmaceutical Re-
search and Development, involving their new drug against 
multi-drug-resistant tuberculosis—and the first anti-tubercu-
losis drug developed in over forty years—Sirturo® (Bedaqui-
line). J&J will contribute the drug at zero cost, so this pilot will 
only refine the measurement of health gains and of the pres-
ervation of the drug’s efficacy. The drug was approved by the 
US Food and Drug Administration in December 2012, and 
once it is approved in India, the pilot in Mumbai will start. 
Different fields, but the same problem 
The same idea that can potentially work really well in phar-
maceuticals could be applied in other fields, such as the agri-
cultural and environmental innovation.
Agriculture and food production face the same dilemma 
between innovation and access. Agricultural innovators 
should have at least the option to agree to the cost-free use 
of their innovation in exchange for payments from public 
funds that are based on the measured total impact of their 
innovation in terms of nutrients produced with given inputs, 
on methane emissions averted, and on reduction in the use 
of pesticides, fertilizers, and antibiotics. 
Environmental innovation could also benefit from this 
strategy. It is of great importance to protect the environment 
because it allows the production of electricity and other 
goods at much lower cost to the environment. However, 
many green technologies—such as efficient solar panels or 
hybrid cars—are patented, and because of high licensing 
fees, they do not diffuse among poorer populations. Once 
again, we are wrongly rewarding innovation in a social issue 
by giving innovators the right to charge high prices, by grant-
ing them a temporary monopoly. Green innovators should be 
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given at least the option to agree to the cost-free use of their 
innovations, in exchange for payments from public funds 
based on the measured total environmental impact of their 
innovations, assessed according to a pre-announced metric. 
A final thought 
Rewarding innovation in the wrong way in the areas of 
pharmaceuticals, food production, and environmental inno-
vation has especially serious effects on the poor. Poor fall ill 
more often and more severely, they die earlier, they suffer 
hunger and malnutrition, and they also suffer more from 
the effects of climate change, as could be seen in the Philip-
pines with Typhoon Haiyan in 2013. And so, incentivizing 
innovation in these social areas in the wrong way perpetu-
ates poverty, and poverty, in turn is a key driver of human 
population growth. 
The crucial variable for the ecological sustainability of 
our planet is the number of human beings who will share its 
limited resources over the coming millennium. Fertility is 
the main indicator for what the human population will be 
like in 2100. Depending on what policies our generation will 
initiate, the United Nations estimates that there will be be-
tween 6 billion and 16 billion people by the end of the cen-
tury (there are 7.2 billion today). Of course, for ecological 
reasons, it would be much better if, in 2100, the world’s 
population was closer to 6 billion than to 16 billion.
The best way of achieving that is by overcoming poverty, 
and one way to do that is by changing the way in which we 
reward medical, agricultural and environmental innovation.
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